Hypereosinophilic Syndrome (HES)

Hypereosinophilic Syndrome (HES) is defined by persistent peripheral blood eosinophilia (absolute eosinophil count ≥1,500 cells/μL on two occasions at least one month apart, or tissue hypereosinophilia) accompanied by evidence of eosinophil-mediated end-organ damage or dysfunction. The condition is rare, with an estimated prevalence of fewer than 1–2 per 100,000 individuals, but carries significant morbidity particularly from cardiac, neurological, and dermatological complications.

HES is not a single disease but rather a clinical syndrome that arises from several distinct underlying mechanisms. In myeloproliferative variants, a clonal hematopoietic driver — most commonly the FIP1L1-PDGFRA fusion gene — leads to autonomous eosinophil overproduction. In lymphocytic variants, an abnormal T-cell clone secretes excessive IL-5 and other eosinophil-promoting cytokines. In idiopathic HES, no underlying driver is identified despite thorough investigation.

The clinical significance of identifying the underlying HES variant is substantial: FIP1L1-PDGFRA-positive myeloproliferative HES responds dramatically to the tyrosine kinase inhibitor imatinib, often achieving complete molecular remission, while other forms require corticosteroid-based or biologic therapies. Comprehensive molecular workup is therefore a mandatory first step in management.

The modern classification of HES is based on identification of the underlying pathogenic mechanism. Accurate subtype classification is essential for treatment planning and prognostication. Each subtype has distinct therapeutic implications.

The clinical manifestations of HES reflect the tissues infiltrated and damaged by activated eosinophils and their toxic granule contents. Symptoms can be insidious in onset, and patients may tolerate significant eosinophilia before presenting with organ dysfunction. Cardiac and neurological complications carry the highest risk of severe morbidity and mortality.

The underlying causes of HES depend on the disease subtype. In myeloproliferative HES, acquired somatic genetic events drive autonomous eosinophil production. In lymphocytic HES, abnormal T-cell clones produce excess eosinophil-promoting cytokines. In idiopathic HES, no driver is identified. Secondary causes of eosinophilia (parasitic infections, atopy, drug reactions) must be excluded before a primary HES diagnosis is made.

Diagnosing HES requires confirming persistent marked eosinophilia, demonstrating eosinophil-mediated end-organ damage, excluding secondary causes, and performing comprehensive molecular subtyping to identify a myeloproliferative or lymphocytic driver. This workup is best conducted at a center with hematology expertise in myeloproliferative and lymphoproliferative disorders.

HES does not use TNM staging. Risk stratification is based on disease variant (myeloproliferative vs lymphocytic vs idiopathic), degree of organ damage at presentation, and response to initial therapy. The myeloproliferative variant carries particular cardiac and thrombotic risk if untreated.

Treatment of HES is guided by the identified disease variant. Rapid identification of FIP1L1-PDGFRA enables prompt initiation of low-dose imatinib with expectation of deep molecular remission. For non-myeloproliferative variants, corticosteroids remain the standard initial therapy, with escalation to steroid-sparing agents or biologics for persistent or refractory disease.

Several advanced therapeutic options are available or under investigation for patients with refractory, steroid-dependent, or high-risk HES. Molecular-targeted approaches and biologic therapies represent the most significant advances in recent years, with ongoing trials continuing to refine treatment strategies.

Biomarker assessment in HES is central to identifying disease subtypes, monitoring treatment response, and detecting molecular resistance. The most clinically actionable biomarker is FIP1L1-PDGFRA, which directly dictates selection of imatinib therapy.

HES is a rare and heterogeneous condition with meaningful diagnostic and therapeutic complexity. Given that treatment selection depends critically on molecular subtyping, and given the risk of serious cardiac complications with delayed treatment, specialist input is strongly recommended in multiple clinical scenarios.

Prognosis in HES varies substantially depending on the disease variant, the extent of organ damage at diagnosis, and response to treatment. FIP1L1-PDGFRA-positive myeloproliferative HES has been transformed by imatinib into a highly manageable condition for the majority of patients. Idiopathic and lymphocytic HES carry more variable outcomes depending on corticosteroid sensitivity and access to biologic therapies. Cardiac involvement at any stage remains the most important determinant of long-term morbidity.

Supportive care in HES addresses the chronic nature of eosinophil-mediated tissue damage, the side effects of long-term treatment, and the monitoring burden of a condition requiring regular laboratory and cardiac assessment. A multidisciplinary approach involving hematology, cardiology, dermatology, neurology, and primary care is important for comprehensive management.